34 Result(s)
-
Article
Open AccessCorrection: Network Meta-analysis of Ravulizumab and Alternative Interventions for the Treatment of Neuromyelitis Optica Spectrum Disorder
-
Article
Open AccessCorrection to: Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) – revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management
-
Article
Open AccessNetwork Meta-analysis of Ravulizumab and Alternative Interventions for the Treatment of Neuromyelitis Optica Spectrum Disorder
Anti-aquaporin-4 antibody-positive (AQP4-Ab+) neuromyelitis optica spectrum disorder (NMOSD) is a complement-mediated autoimmune disease in which unpredictable and relapsing attacks on the central nervous syst...
-
Article
Open AccessUpdate on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) – revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management
This manuscript presents practical recommendations for managing acute attacks and implementing preventive immunotherapies for neuromyelitis optica spectrum disorders (NMOSD), a rare autoimmune disease that cau...
-
Article
Open AccessUpdate on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD) – revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosis
The term ‘neuromyelitis optica spectrum disorders’ (NMOSD) is used as an umbrella term that refers to aquaporin-4 immunoglobulin G (AQP4-IgG)-positive neuromyelitis optica (NMO) and its formes frustes and to a nu...
-
Article
Open AccessMultiple Sklerose Therapie Konsensus Gruppe (MSTKG): Positionspapier zur verlaufsmodifizierenden Therapie der Multiplen Sklerose 2021 (White Paper)
Die Multiple Sklerose ist eine komplexe, autoimmun vermittelte Erkrankung des zentralen Nervensystems, charakterisiert durch inflammatorische Demyelinisierung sowie axonalen/neuronalen Schaden. Die Zulassung v...
-
Article
Von der Neuromyelitis optica zur Neuromyelitis-optica-Spektrum-Erkrankung: vom klinischen Syndrom zur Klassifikation
Die Neuromyelitis-optica-Spektrum-Erkrankung („neuromyelitis optica spectrum disorder“, NMOSD) – abgeleitet von NMO oder „Devic-Syndrom“ – wird seit Entdeckung des Anti-Aquaporin-4-Serumantikörpers (AQP4-IgG) ...
-
Article
Open AccessRetinal layers and visual conductivity changes in a case series of microangiopathic ischemic stroke patients
It is unknown whether microangiopathic ischemic strokes outside the visual pathway go along with subclinical changes of the retinal structure or the visual system. The objectives of this prospective non-interv...
-
Article
Erratum zu: Ocrelizumab zur Behandlung der Multiplen Sklerose
Der Beitrag enthält eine fehlerhafte Tab. 3. Bitte beachten Sie im Folgenden die korrigierte Version der Tabelle. Wir bitten Sie, diese zu beachten und den Fehler zu …
-
Article
Open AccessOcrelizumab zur Behandlung der Multiplen Sklerose
Ocrelizumab ist ein monoklonaler Antikörper, der sich gegen das Differenzierungsantigen CD20 richtet und zu einer effektiven längerfristigen Depletion von Lymphozyten, insbesondere von B‑Zellen, führt. Unlängs...
-
Article
COVID-19 and management of neuroimmunological disorders
The importance of reported neurological manifestations of coronavirus disease 2019 (COVID-19) is still unclear. Nevertheless, an immediate and ongoing neurological challenge posed by the COVID-19 pandemic is t...
-
Article
Open AccessCryptococcal meningoencephalitis in an IgG2-deficient patient with multiple sclerosis on fingolimod therapy for more than five years – case report
Fingolimod (Gilenya®), a first-in-class sphingosine-1-phosphate receptor modulator is approved for the treatment of relapsing-remitting multiple sclerosis. Fingolimod-induced selective immunosuppression leads ...
-
Article
Open AccessMeningitis gone viral: description of the echovirus wave 2013 in Germany
Aseptic meningitis epidemics may pose various health care challenges.
-
Article
Open AccessExtensive immune reconstitution inflammatory syndrome in Fingolimod-associated PML: a case report with 7 Tesla MRI data
Progressive multifocal leukoencephalopathy (PML) is a rare complication of patients treated with fingolimod.
-
Article
Drug Treatment of Clinically Isolated Syndrome
Multiple sclerosis (MS) is an autoimmune disease of the central nervous system (CNS) that leads to inflammation, demyelination and ultimately axonal degeneration. In most cases, it is preceded by its precursor...
-
Article
Clinical presentation of Moyamoya angiopathy in Europeans: experiences from Germany with 200 patients
Moyamoya angiopathy (MMA) is a rare vasopathy, especially among European Caucasians. Data about demographics, clinical presentation, comorbid conditions, radiological findings as well as laboratory and cerebra...
-
Article
Misdiagnoses and delay of diagnoses in Moyamoya angiopathy—a large Caucasian case series
The lacking awareness of healthcare providers bears the risk of delayed or false diagnoses in rare diseases. No systematic data about misdiagnoses of Moyamoya angiopathy (MMA) are available.
-
Article
Managing Risks with Immune Therapies in Multiple Sclerosis
Since the introduction of the interferons in the 1990s, a multitude of different immunomodulatory and immunosuppressant disease-modifying therapies for multiple sclerosis (MS) have been developed. They have al...
-
Article
Open AccessAssessment of Opicinumab in Acute Optic Neuritis Using Multifocal Visual Evoked Potential
Multifocal visual evoked potential (MF-VEP) assesses a wider visual field than full-field VEP (FF-VEP) and potentially offers a more precise analysis of optic nerve injury and repair following optic neuritis. ...
-
Article
Optical coherence tomography for the diagnosis and monitoring of idiopathic intracranial hypertension
The objectives of the study were to investigate the value of optical coherence tomography in detecting papilledema in patients with idiopathic intracranial hypertension (IIH), a disease which is difficult to m...
